BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
Nvidia Denies Upfront Payment Requirement for H200 AI Chips Amid China Export Scrutiny 
SK Hynix to Invest $13 Billion in Advanced Chip Packaging Plant as AI Memory Demand Surges 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable” 
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
NYC Nurses Strike Shuts Down 10 Private Hospitals as 15,000 Demand Safer Staffing and Benefits 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
Lynas CEO Amanda Lacaze to Retire After 12 Years as Rare Earths Demand Grows 
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
WARREN, N.J., March 27, 2017 -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced a poster presentation at the 37th Annual Meeting for the International Society for Heart and Lung Transplantation (ISHLT) which will take place in San Diego, CA, from April 5 to 8. The poster will feature data from an investigator-led study of INOpulse® in patients with pulmonary arterial hypertension (PAH).
| Title: | Effects of Ambulatory Inhaled Nitric Oxide on Exercise Induced Increases in Pulmonary Pressures | |
| Authors: | R. A. Davey (Division of Cardiology, Western University, London, ON), A. Raina, R. L. Benza (Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, PA) | |
| Date: | Thursday, April 6 | |
| Time: | 6:15 – 7:15 pm Pacific Time | |
| Session: | Poster Session 2 | |
Pulmonary arterial hypertension (PAH) is characterized by progressive increases in pulmonary vascular resistance (PVR) and subsequent reductions in cardiac output; these changes are further worsened by exercise. Inhaled nitric oxide (iNO) can decrease PVR and improve cardiac output in PAH patients.
In this study, the investigators looked at the effects of pulsed iNO on PVR and cardiac output in PAH patients with the CardioMEMS, an implantable hemodynamic monitoring device, both before and after exercise. Inhaled NO was delivered using Bellerophon’s proprietary INOpulse delivery system, that provides pulsed iNO in the ambulatory setting. The INOpulse delivery system is designed to be used chronically in outpatients and is currently in Phase 3 clinical trials for PAH.
About ISHLT
The International Society for Heart and Lung Transplantation (ISHLT) is a not-for-profit, multidisciplinary, professional organization dedicated to improving the care of patients with advanced heart or lung disease through transplantation, mechanical support and innovative therapies via research, education and advocacy. ISHLT was founded in 1981 and today has more than 3,400 members from over 45 countries, representing over 15 different professional disciplines involved in the management and treatment of end-stage heart and lung disease. The 37th Annual Meeting and Scientific Sessions will take place at the Manchester Grand Hyatt, San Diego, April 5 – 8. For more information, refer to http://www.ishlt.org/meetings/annualMeeting.asp.
About Bellerophon
Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company is currently developing three product candidates under its INOpulse program, a proprietary pulsatile nitric oxide delivery system. The first is for the treatment of pulmonary arterial hypertension (PAH), for which the Company has commenced Phase 3 clinical trials in 2016. The second is for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD) and the third candidate is for the treatment of pulmonary hypertension associated with Idiopathic Pulmonary Fibrosis (PH-IPF), both of which are in Phase 2 development. For more information, please visit www.bellerophon.com.
Contacts At Bellerophon: Fabian Tenenbaum, Chief Executive Officer (908) 574-4767 At LifeSci Advisors: Bob Yedid (646) 597-6989 [email protected]
